Personalized Medicine – Multimedia

Can we use computational methods to identify previously unknown off-targets of PARP inhibitors that can explain their observed differences?

Dr. Jeffrey Trent and Dr. Muhammad Murtaza of TGen, an affiliate of City of Hope, discuss the significance of liquid biopsies in the diagnoses and management of life-threatening diseases.

In this list we take a look at 6 researchers whose contributions have helped (and are continuing to help) drive the field forward.

This list highlights 7 enormous projects that are harnessing the power of big data to solve big problems in science.

In this list, we pay homage to 9 of the most incredible images we’ve seen from the field of cancer research.

The proteome is the most functional component encoded for in the genome. Advances in proteomic technologies allow comprehensive profiling of of signaling pathways, precise expression of therapeutic targets in tissues and cellular subcompartments, and of metabolomic features that determine likelihood of therapeutic response. Moreover the current paradigm shift in cancer therapy with dramatic and durable responses to antibody and checkpoint therapeutics that trascend tumor genomic profiles further emphasize opportunities to identify novel targets and tailor treatment based on their expression patterns. The potential for personalizing cancer treatment based on proteomic and metabolomic profiles will be presented for epithelial type tumors including lung and pancreatic cancer.

Learn about how Personalized Medicine is changing how drugs are being developed and how healthcare is being delivered, and how Horizon is helping to enable this change.

The IntelliQube® from Douglas Scientific® is designed to address the need for accurate and reliable results for studies such as CNV determination.

The High Throughput Biomedicine unit at FIMM Technology Centre provides a wide range of biomedical high throughput assays.

This presentation will outline key issues in oncology biomarker testing and describe findings from a study of practices used by National Cancer Institute (NCI) designated cancer centers, the leading U.S. oncology institutions, for testing key biomarkers in three solid tumors - breast, gastroesophageal and non-small cell lung cancers.